1. Niskanen L, Turpeinen A, Penttila I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998; 21 (11): 1861–9.
2. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141–7.
3. Neaton JD, Wentworth DN, Cutler J et al. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Reasearch Group. Ann Epidemiol 1993; 3: 493–9.
4. Stratton JM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. BMJ 2000; 321: 405–12.
5. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014–9.
6. Jeerakathil T, Johnson J, Simpson S et al Short-Term Risk for Stroke Is Doubled in Persons With Newly Treated Type 2 Diabetes Compared With Persons Without Diabetes. Stroke 2007; 38: 1739–43.
7. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
9. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17.
10. Selvin E, Bolen S, Hsin-Chieh Yeh et al. A Systematic Review Cardiovascular Outcomes in Trials of Oral Diabetes Medications. Arch Intern Med 2008; 168 (19): 2070–80.
11. Johnson JA, Simpson SH, Majumdar SR, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244–8.
12. Evans M, Ogston S, Emslie-Smith A, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930–6.
13. Duckworth W, Abraira C, Moritz T et al. (VADT Investigators). Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears. N Engl J Med 2009; 361: 1024–5, 1028. N Engl J Med 2009; 360: 129–39.
14. Lindstrom T, Jorfeldt L, Tegler L et al. Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med 1992; 9: 536–41.
15. Landstedt-Hallin L, Englund A, Adamson U et al. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999; 246: 299–307.
16. Gore O, McGuire D. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53.
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. 
N Engl J Med 2008; 358: 2545–59.
18. Мисникова И.В., Древаль А.В., Ковалева Ю.А.. Риски общей и сердечно-сосудистой смертности, а также инфаркта миокарда и острого нарушения мозгового кровообращения у больных сахарным диабетом 2 типа в зависимости от вида стартовой сахароснижающей терапии. Сахарный диабет. 2009; 4: 71–9.
19. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой и др. Сахарный диабет (Прил.). 2011; 3.
20. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation 1986; 74: 1124–36.
21. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning on dogs. Circ Res 1992; 70: 223–33.
22. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischemic precondioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992; 26: 1054–62.
23. Garlid KD, Paucek P, Yarov-Yarovoy V et al. Cardioprotective effects of diazoxide and its interaction with mitochondrial ATP-sensitive K-channels. Circ Res 1997; 81: 1072–82.
24. Liu Y, Sato T, O’Rouke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97: 2463–9.
25. Patel DJ, Purcell H, Fox KM. Cardioprotection by opening of the Katpchannel in unstable angina: is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. Eur Heart J 1999; 20: 51–7.
26. Garlid KD, Dos Santos P et al. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+channel in cardiac function and cardioprotection. Biochimica et Biophysica Acta 2003; 1606: 1–21.
27. Tomai F et al. Effects of Katp channel blockade by glibenclamide on the warm-up phenomen. Eur Heart J 1999; 20: 196–202.
28. Nagashima K, Takahashi A, Ikeda H et al. Sulfonylurea and non-sulfanylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res Clin Practice 2004; 66 S: S75–78.
29. Quast U, Stephan D, Bieger S, Russs U. The Impact of ATP-Sensitive K+Channel Subtype Selectivity of Insuline Secretagogues for the Coronary Vasculature and the Myocardium. Diabetes 2004; 53 (Suppl. 3): S156–64.
30. Nathan DM, Buse JB, Davidson MB et al. Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2008; 31: 1–11.
31. Evans M, Ogston S, Emslie-Smith A, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930–6.
32. Selvin E, Bolen S, Hsin-Chieh Yeh et al. A Systematic Review Cardiovascular Outcomes in Trials of Oral Diabetes Medications. Arch Intern Med 2008; 168 (19): 2070–80.
33. Isoda K, Young JL, Zirlik A et al. Metformin inhibits proinflammatory responses and nuclear factorkappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26: 611–7.
34. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006; 55: 496–505.
35. Detaille D, Guigas B, Chauvin C et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179–87.
36. Шамхалова М.Ш., Зайцева Н.В., Курумова К.О., Шестакова М.В. Контрастиндуцированная нефропатия у больных сахарным диабетом. Трудный пациент. 2007; 4: 15–9.
37. Monami M, Luzzi C, Chiasserini V et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477.

О.Г.Компаниец 

Кафедра клинической фармакологии ГОУ ВПО КГМУ